Compare · AVTR vs CTKB
AVTR vs CTKB
Side-by-side comparison of Avantor Inc. (AVTR) and Cytek Biosciences Inc. (CTKB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and CTKB operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $6.41B, about 12.5x CTKB ($511.4M).
- Over the past year, AVTR is down 30.1% and CTKB is up 20.4% - CTKB leads by 50.4 points.
- CTKB has been more active in the news (12 items in the past 4 weeks vs 2 for AVTR).
- AVTR has more recent analyst coverage (25 ratings vs 13 for CTKB).
- Company
- Avantor Inc.
- Cytek Biosciences Inc.
- Price
- $9.39-2.80%
- $3.96-1.25%
- Market cap
- $6.41B
- $511.4M
- 1M return
- +19.31%
- +7.90%
- 1Y return
- -30.08%
- +20.36%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2021
- News (4w)
- 2
- 12
- Recent ratings
- 25
- 13
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Latest AVTR
- Wolfe Research resumed coverage on Avantor with a new price target
- SEC Form SD filed by Avantor Inc.
- Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
- RBC Capital Mkts resumed coverage on Avantor with a new price target
- Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Murthy Mala was granted 25,270 shares, increasing direct ownership by 57% to 69,479 units (SEC Form 4)
- Director Lucier Gregory T was granted 25,270 shares and bought $83,200 worth of shares (10,000 units at $8.32), increasing direct ownership by 289% to 34,006 units (SEC Form 4)
- Director Dingemans Simon was granted 25,270 shares, increasing direct ownership by 406% to 31,495 units (SEC Form 4)
- Director Massaro Joseph R was granted 25,270 shares, increasing direct ownership by 48% to 77,408 units (SEC Form 4)
- Director Makin Louise was granted 25,270 shares, increasing direct ownership by 116% to 47,140 units (SEC Form 4)
Latest CTKB
- Director Ball Jack converted options into 43,973 shares, increasing direct ownership by 103% to 86,678 units (SEC Form 4)
- SEC Form 4 filed by Director Muir Glenn P
- SEC Form 3 filed by new insider Muir Glenn P
- SEC Form 4 filed by Director Chin Richard
- Director Imper Vera converted options into 43,973 shares, increasing direct ownership by 280% to 59,679 units (SEC Form 4)
- Director Neff Deborah J converted options into 43,973 shares, increasing direct ownership by 280% to 59,679 units (SEC Form 4)
- Director Holder Michael converted options into 43,973 shares, increasing direct ownership by 263% to 60,694 units (SEC Form 4)
- Cytek Biosciences to participate at the Singular Research's Las Vegas Invitational Conference
- Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
- Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026